View source for Ficlatuzumab

{{Short description|Monoclonal antibody}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457119832
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = zu/o
| target            = [[Hepatocyte growth factor|HGF]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1174900-84-5
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| KEGG = D10123
| KEGG_Ref = {{keggcite|changed|kegg}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 77E89833TG
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| C=6446 | H=9954 | N=1718 | O=2026 | S=46
}}

'''Ficlatuzumab''' is a humanized monoclonal antibody designed for the treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref>

It is a humanized monoclonal antibody that binds to [[hepatocyte growth factor]], thus inhibiting the [[c-MET]] receptor signaling cascade.<ref name="pmid33725344">{{cite book | vauthors = Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A | title = Reviews on New Drug Targets in Age-Related Disorders | chapter = A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer | series = Advances in Experimental Medicine and Biology | volume = 1286 | pages = 49–64 (57) | date = 2021 | pmid = 33725344 | doi = 10.1007/978-3-030-55035-6_3 | isbn = 978-3-030-55034-9 | s2cid = 232261340 }}</ref>

Ficlatuzumab was developed by AVEO Pharmaceuticals.  In May 2012, AVEO released results of a Phase II clinical trial comparing [[gefitinib]] alone and in combination with ficlatuzamab in treatment-naive Asian patients with [[non-small cell lung cancer]].<ref>{{Citation |date=May 3, 2012 |title=AVEO Releases Phase 2 Data |periodical=[[Drug Discovery & Development]] |at=dddmag.com |url=http://www.dddmag.com/news/2012/05/aveo-releases-phase-2-data |access-date=June 3, 2012 }}</ref>

== References ==
{{reflist}}

{{monoclonals for tumors}}
{{Growth factor receptor modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}